About Alcyomics

Alcyomics is a UK service company offering Skimune™ for the safety assessment of novel compounds and drugs including monoclonal antibodies. Skimune™ is a unique human skin explant non 3D equivalent assay demonstrating potency via histopathological damage  for assessment of immunogenicity.

Results show degree of damage/ potency  by novel compounds graded in severity  from
I (A) to III (C)

Advantages to Industry

•    Assessment of potency/contact sensitivity and allergy
•    Reduces animal testing and cost of pre-clinical drug development
•    Shows human skin reactions not possible with 3D skin equivalent models
•    Increases product safety profile
•    Assesses immunogenicity / predicts responses
•    Distinguishes between high and low potency compounds
•    Fast evaluation using screening assay

Applications

•    Safety testing using human in vitro skin explant assay (Skimune™)
•    Screening-up to 30 compounds in one assay
•    Distinguishes between sensitiser versus non sensitiser and allergen versus non      allergen in one assay
•    Potency assessment  on novel compounds
•    The assay also aids development of  novel monoclonal antibodies detecting       immunogenicity, safety, efficacy & predicts response. Also asseses
      immunomodulatory activity of novel inhibitors/monoclonal antibodies.
•    Aids development of novel compounds in the absence of animal testing, providing      accurate, reliable results within 10-4 days.
•    Downstream mRNA, microRNA, cytokine release assays, immunohistochemistry of      targets